Skip to content

Dolasetron

Serotonin-3 Receptor Antagonist — ALIMENTARY TRACT AND METABOLISM

Also known as: anemet, anzemet, anzemet hydrate, dolasetron mesilate, dolasetron mesylate, dolasetron mesylate hydrate, dolasetron methanesulfonate hydrate, MDL 73,147EF

OfmFDA approvedATC A04AA04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Dolasetron is an ofm drug in the Serotonin-3 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Serotonin 3 Receptor Antagonists. DrugCentral lists 2 molecular targets, including HTR3A and KCNH2. Recorded indications include Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.

  • Approval status: ofm (first approved 1997 by the FDA).
  • Drug class: Serotonin-3 Receptor Antagonist.
  • Mechanism of action: Serotonin 3 Receptor Antagonists.
  • Molecular targets: HTR3A and KCNH2 (2 listed in DrugCentral).
  • Indications: Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.
  • ATC code: A04AA04 (Serotonin (5HT3) antagonists).
  • Molecular formula: C19H20N2O3; molecular weight 324.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Post-Operative Nausea and Vomiting
  • Prevention of Post-Operative Nausea and Vomiting

Contraindications (12)

  • Atrioventricular Conduction Defect
  • Bradycardia
  • Chemotherapy-induced nausea and vomiting
  • Chronic heart failure
  • Congenital long QT syndrome
  • Doxorubicin Induced Cardiomyopathy
  • Heart block
  • Hypokalemia
  • Hypomagnesemia
  • Kidney disease
  • Prolonged QT interval
  • Torsades de pointes

Mechanism & targets

Mechanism of action (MoA)Serotonin 3 Receptor Antagonists
Established pharmacologic classSerotonin-3 Receptor Antagonist

Molecular targets (2)

TargetGeneActionActivity
5-hydroxytryptamine receptor 3AHTR3AantagonistKi 7.70
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 5.23

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1997-09-11FDA—SANOFI AVENTIS US

ATC classification

ATC codeTherapeutic hierarchy
A04AA04ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Serotonin (5HT3) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Death385.6
Disease progression96.0
Off label use95.3
Fatigue79.8
Nausea68.9
Asthenia48.6
Myelosuppression38.4

Chemical structure

Molecular formulaC19H20N2O3
Molecular weight324.38 g/mol
CAS number115956-12-2
InChIKeyUKTAZPQNNNJVKR-MMUVGSQPSA-N
PubChem CID3033818
O=C(O[C@H]1C[C@H]2CC3C[C@@H](C1)N2CC3=O)C1=CNC2=C1C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dolasetron used for?

DrugCentral lists the following indications for Dolasetron: Post-Operative Nausea and Vomiting and Prevention of Post-Operative Nausea and Vomiting.

How does Dolasetron work?

Dolasetron is classified as Serotonin 3 Receptor Antagonists; its molecular targets in DrugCentral include HTR3A (antagonist) and KCNH2.

When was Dolasetron first approved?

Dolasetron was first approved by the FDA in 1997.

What drug class does Dolasetron belong to?

Dolasetron is in the Serotonin-3 Receptor Antagonist class.

What is the chemical formula of Dolasetron?

Dolasetron has the molecular formula C19H20N2O3 and a molecular weight of 324.38 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1997-09-11
AgencyFDA
Targets2
Indications2
FormulaC19H20N2O3
DrugCentral ID3931
Interactive profile